This abstract reports that patients with ESRD 2/2 to GPA have a higher risk of vertebral fractures compared to individuals with ESRD without GPA. Even low dose steroids (pred 5mg) taken during the first year of HD conferred an increase risk or facture! #ACR24 @RheumNow https://t.co/4xM3XTCHSH

Briefly highlighting this poster, always looking for a non-Georg Schett CAR-T study to see if their results replicate All 10 pts in this one had a "complete humoral response," normalizing antibodies & experiencing long term drug-free remission #ACR24 @RheumNow Abstr#0673 https://t.co/pjOjRnJVhO

A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/2t8xcYJ3UV

This poster makes me happy for so many reasons 😆 Aggressive & descriptive title? ☑️ Pretty chloropleth map? ☑️ Dunks on hamfisted EMR tools trying to replace patient-physician interactions? ☑️ @RheumNow #ACR24 Abstr#0668 ThereAreNoShortcuts https://t.co/IXYaHAi15q

This is likely an oversimplification, but I've been looking for exactly this diagram Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition @EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No? @rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3

A study from the EuroSpA collaboration validates new BASDAI cut-offs for disease activity in axial spondyloarthritis based in ASDAS: <1.4 for remission, <2.8 for low activity, and >5.9 for very high activity. This research enhances our understanding of disease states and their… https://t.co/OkPiTwSHz6 https://t.co/NjIDeme9dm

Ok so trivial tweet here but I just love the name of this outcome measure... "LFA-REAL" 😄😆 Serious topic though; PRO's are huge in SLE research! @RheumNow #ACR24 Abstr#0626 https://t.co/w34zTNjSbH

The use of ultrasound in clinically suspect arthralgia can complement MRI early diagnosis of RA. Abstr#228 Gupta A @RheumNow #ACR24 https://t.co/rpVqZKeMXE

#0600 🔬BKZ achieves sustained impact in PsA ➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naïve & TNFi-IR PsA pts ➡️Pain,function,fatigue & skin showed greatest & sustained reductions @ 2 yrs👇 🎯BKZ offers sustained response in 🔑PsA domains #ACR24 @RheumNow https://t.co/uhzZoOrr3H

🌟 Join us for the Aging Strong session at #ACR24! We are thrilled to have Dr Cynthia Boyd, division director of Geriatrics at Hopkins, visit us to discuss how to manage multicomplexity in older rheumatic patients. #GeriRheum @RheumNow @cynthiaboyd16 @UnaMakris https://t.co/QZpOmdgzOR